A Dose-Response Strategy Reveals Differences between Normal-Weight and Obese Men in Their Metabolic and Inflammatory Responses to a High-Fat Meal.

A dose-response strategy may not only allow investigation of the impact of foods and nutrients on human health but may also reveal differences in the response of individuals to food ingestion based on their metabolic health status. In a randomized crossover study, we challenged 19 normal-weight (BMI: 20-25 kg/m(2)) and 18 obese (BMI: >30 kg/m(2)) men with 500, 1000, and 1500 kcal of a high-fat (HF) meal (60.5% energy from fat). Blood was taken at baseline and up to 6 h postprandially and analyzed for a range of metabolic, inflammatory, and hormonal variables, including plasma glucose, lipids, and C-reactive protein and serum insulin, glucagon-like peptide-1, interleukin-6 (IL-6), and endotoxin. Insulin was the only variable that could differentiate the postprandial response of normal-weight and obese participants at each of the 3 caloric doses. A significant response of the inflammatory marker IL-6 was only observed in the obese group after ingestion of the HF meal containing 1500 kcal [net incremental AUC (iAUC) = 22.9 ± 6.8 pg/mL × 6 h, P = 0.002]. Furthermore, the net iAUC for triglycerides significantly increased from the 1000 to the 1500 kcal meal in the obese group (5.0 ± 0.5 mmol/L × 6 h vs. 6.0 ± 0.5 mmol/L × 6 h; P = 0.015) but not in the normal-weight group (4.3 ± 0.5 mmol/L × 6 h vs. 4.8 ± 0.5 mmol/L × 6 h; P = 0.31). We propose that caloric dose-response studies may contribute to a better understanding of the metabolic impact of food on the human organism. This study was registered at clinicaltrials.gov as NCT01446068.

Época de aplicação da primeira dose de nitrogênio em cobertura em milho e espécies antecessoras de cobertura de inverno

Atualmente, os critérios utilizados no Sul do Brasil para definição da dose de nitrogênio (N) a ser aplicada no milho são o teor de matéria orgânica no solo, a expectativa de rendimento da cultura e as características da cultura antecessora. Embora apresente alta relação carbono:nitrogênio (C/N), a aveia preta é a espécie de cobertura de solo de inverno mais utilizada como antecessora às culturas comerciais de verão. Essa característica pode resultar em imobilização do N do solo, deficiência de N na planta de milho e redução no rendimento de grãos. Embora na determinação da dose a ser aplicada sejam consideradas as espécies antecessoras, os avanços quanto à melhor época para aplicar N em cobertura em milho foram pequenos. Com o objetivo de avaliar a época mais adequada para aplicação da primeira dose de N em cobertura no milho cultivado em sucessão a espécies de inverno com distintas relações C/N, um experimento foi realizado em vasos em casa de vegetação em Porto Alegre-RS. Utilizaram-se colunas de solo não deformado, classificado como Argissolo Vermelho distrófico típico. Os tratamentos constaram de quatro sistemas de coberturas de solo de inverno (aveia preta, ervilhaca comum, nabo forrageiro e pousio) e três formas de manejo de N em cobertura (com aplicação de N nos estádios V3 ou V5 e sem aplicação de N em cobertura). O delineamento experimental foi o completamente casualizado, em esquema fatorial 4 x 3, com três repetições. Procedeu-se à análise de variância pelo teste F e à comparação de médias pelo teste de Tukey (p < 0,05). A aveia, que tem alta relação C/N, apresentou baixa taxa de mineralização e de liberação de N de seus resíduos, enquanto as culturas de ervilhaca comum e nabo forrageiro mostraram relação C/N mais estreita, estimulando esses processos. Com o uso de aveia como cultura antecessora ao milho, verificou-se diminuição dos teores de N mineral no solo e de N total na planta de milho, independentemente da época de aplicação de N em cobertura, diminuindo o desenvolvimento inicial da planta. Em sucessão à ervilhaca comum e ao nabo forrageiro, o teor relativo de clorofila na folha e a produção de massa seca de milho, avaliados no estádio V7, foram maiores em relação aos obtidos em sucessão à aveia preta, independentemente da época de aplicação da primeira dose de N em cobertura. Os dados obtidos evidenciaram ser possível retardar a época de aplicação da primeira dose de N em cobertura em milho do estádio V3 para V5, quando o milho for cultivado em sucessão a espécies de inverno com baixa relação C/N.

Fluxo difusivo de micronutrientes catiônicos afetado pelo tipo, dose e época de incorporação de adubos verdes ao solo

Os solos brasileiros, principalmente os do cerrado, são bastante intemperizados e pobres em alguns micronutrientes catiônicos na solução do solo. A utilização de técnicas de manejo, como a adubação verde, pode favorecer o fluxo difusivo (FD) e a disponibilidade desses nutrientes para as plantas. O presente trabalho visou avaliar se a incorporação de adubos verdes ao solo, em diferentes doses e épocas, modifica o FD e a forma iônica de transporte dos micronutrientes Zn, Cu, Fe e Mn no solo. Para tanto, foram incorporados dois resíduos vegetais largamente cultivados como adubo verde: o feijão guandu (Cajanus cajan) ou o milheto (Pennisetum americanum) por diferentes períodos (0, 15, 25, 35, 45 e 55 dias) e doses (0, 9, 18 e 36 t ha-1) num Latossolo Vermelho, argiloso, em condições de laboratório. Para avaliar o FD, utilizaram-se resinas de troca aniônica (positivamente carregada) e de troca catiônica (negativamente carregada) na forma de lâmina, incubadas junto ao solo em câmaras de difusão durante 15 dias. Os resultados obtidos demonstraram que houve aumento do FD do Cu e do Fe com o aumento das doses de material vegetal, principalmente no início do período de incubação, e maior fluxo desses dois micronutrientes para a resina aniônica em relação à catiônica, possivelmente por ser o seu transporte no solo mais dependente da formação de complexos organometálicos com carga líquida negativa. Já para Zn e Mn, o fluxo difusivo foi maior para a resina catiônica. O aumento do tempo de incubação favoreceu o fluxo difusivo de Mn e Zn e reduziu o do Cu e Fe.

When "enough" is not enough: new perspectives on optimal methadone maintenance dose.

Some methadone maintenance treatment (MMT) programs prescribe inadequate daily methadone doses. Patients complain of withdrawal symptoms and continue illicit opioid use, yet practitioners are reluctant to increase doses above certain arbitrary thresholds. Serum methadone levels (SMLs) may guide practitioners dosing decisions, especially for those patients who have low SMLs despite higher methadone doses. Such variation is due in part to the complexities of methadone metabolism. The medication itself is a racemic (50:50) mixture of 2 enantiomers: an active "R" form and an essentially inactive "S" form. Methadone is metabolized primarily in the liver, by up to five cytochrome P450 isoforms, and individual differences in enzyme activity help explain wide ranges of active R-enantiomer concentrations in patients given identical doses of racemic methadone. Most clinical research studies have used methadone doses of less than 100 mg/day [d] and have not reported corresponding SMLs. New research suggests that doses ranging from 120 mg/d to more than 700 mg/d, with correspondingly higher SMLs, may be optimal for many patients. Each patient presents a unique clinical challenge, and there is no way of prescribing a single best methadone dose to achieve a specific blood level as a "gold standard" for all patients. Clinical signs and patient-reported symptoms of abstinence syndrome, and continuing illicit opioid use, are effective indicators of dose inadequacy. There does not appear to be a maximum daily dose limit when determining what is adequately "enough" methadone in MMT.

Topical therapy is underused in patients with ulcerative colitis.

The availability of new topical preparations for the treatment of left sided ulcerative colitis offers a therapy optimization for many patients. Rectal application of steroids and 5-aminosalicylic acid (5-ASA) is associated with fewer side effects and has a higher therapeutic efficacy in left-sided colitis as compared to a systemic therapy. Therefore, we were interested in the use of topical therapy in patients with ulcerative colitis. The key question was whether topical treatment is more frequently used than oral therapy in patients with proctitis and left sided colitis. Data of 800 patients of the Swiss IBD cohort study were analyzed. Sixteen percent of patients of the cohort had proctitis, 21% proctosigmoiditis and 41% pancolitis. Topical therapy with 5-ASA or corticosteroids was given in 26% of patients with proctitis, a combined systemic and topical treatment was given in 13%, whereas systemic treatment with 5-ASA without topical treatment was given in 29%. Proportion of topical drug use decreased with respect to disease extension from 39% for proctitis to 13.1% for pancolitis (P=0.001). Patients with severe colitis received a significantly higher dose of topical 5-ASA than patients in remission. Side effects of topical or systemic 5-ASA or budesonide treatment were less frequently seen compared to other medications. Topical treatment was frequently stopped over time. The quality of life was the same in patients with limited disease compared to patients with pancolitis. Topical treatment in proctitis patients was underused in Switzerland. Since topical treatment is safe and effective it should be used to a larger extend.

Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity.

OBJECTIVE: We investigated whether the oral administration of a low dose (75 micro g) of midazolam, a CYP3A probe, can be used to measure the in vivo CYP3A activity. METHODS: Plasma concentrations of midazolam, 1'OH-midazolam and 4'OH-midazolam were measured after the oral administration of 7.5 mg and 75 micro g midazolam in 13 healthy subjects without medication, in four subjects pretreated for 2 days with ketoconazole (200 mg b.i.d.), a CYP3A inhibitor, and in four subjects pretreated for 4 days with rifampicin (450 mg q.d.), a CYP3A inducer. RESULTS: After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively. No side effects were reported by the subjects taking this low dose of midazolam. Good correlations were observed between the 30-min total 1'OH-midazolam/midazolam ratio and midazolam clearance in the group without co-medication (r(2)=0.64, P<0.001) and in the three groups taken together (r(2)=0.91, P<0.0001). Good correlations were also observed between midazolam plasma levels and midazolam clearance, measured between 1.5 h and 4 h. CONCLUSION: A low oral dose of midazolam can be used to phenotype CYP3A, either by the determination of total 1'OH-midazolam/midazolam ratios at 30 min or by the determination of midazolam plasma levels between 1.5 h and 4 h after its administration.

Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk

OBJECTIVES: To investigate the effect of low-dose aspirin administered in the morning or evening on the rate of discontinuation of prolonged-release nicotinic acid (Niaspan) due to flushing in patients at elevated cardiovascular risk. RESEARCH DESIGN AND METHODS: This was an observational, non-interventional study in patients at elevated cardiovascular risk due to cardiovascular disease or type 2 diabetes. Patients received prolonged-release nicotinic acid and aspirin under the usual care of their physician for 15 weeks. MAIN OUTCOME MEASURES: The main outcome measure was the rate of treatment discontinuation for flushing. Other adverse drug reactions (ADRs) were also recorded. Lipid parameters were also measured. RESULTS: The patient population included 539 subjects (70% male); 36% had type 2 diabetes, 80% had prior cardiovascular disease, and 37% had a family history of cardiovascular disease. The rate of treatment discontinuation due to flushing did not differ (p = 0.3375) between the morning aspirin group (10.6%) and the evening aspirin group (13.8%). The overall incidence of flushing was 57%. Most flushes were of mild or moderate severity and decreases occurred over time in both frequency and intensity. ADRs unrelated to flushing occurred in 6.6% of the morning aspirin group and 7.4% of the evening aspirin group. HDL-cholesterol increased by +21.3% in the overall population, together with moderate improvements in other lipid parameters. CONCLUSIONS: Flushing was the most common ADR with prolonged-release nicotinic acid treatment, as expected. The timing of aspirin administration did not influence the rate of treatment discontinuations for flushing. Marked increases in HDL-cholesterol were observed.

Optimization of centrifugal separation of Ó-lactalbumin and ¿̐ư-lactoglobulin

Selostus: Ó-lactalbumiinin ja ¿̐ư-lactoglobuliinin sentrifugointierotuksen optimointi

Safe and effective variability-a criterion for dose individualization.

BACKGROUND: : A primary goal of clinical pharmacology is to understand the factors that determine the dose-effect relationship and to use this knowledge to individualize drug dose. METHODS: : A principle-based criterion is proposed for deciding among alternative individualization methods. RESULTS: : Safe and effective variability defines the maximum acceptable population variability in drug concentration around the population average. CONCLUSIONS: : A decision on whether patient covariates alone are sufficient, or whether therapeutic drug monitoring in combination with target concentration intervention is needed, can be made by comparing the remaining population variability after a particular dosing method with the safe and effective variability.

Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model.

The pharmacokinetics (PK) of efavirenz (EFV) is characterized by marked interpatient variability that correlates with its pharmacodynamics (PD). In vitro-in vivo extrapolation (IVIVE) is a "bottom-up" approach that combines drug data with system information to predict PK and PD. The aim of this study was to simulate EFV PK and PD after dose reductions. At the standard dose, the simulated probability was 80% for viral suppression and 28% for central nervous system (CNS) toxicity. After a dose reduction to 400 mg, the probabilities of viral suppression were reduced to 69, 75, and 82%, and those of CNS toxicity were 21, 24, and 29% for the 516 GG, 516 GT, and 516 TT genotypes, respectively. With reduction of the dose to 200 mg, the probabilities of viral suppression decreased to 54, 62, and 72% and those of CNS toxicity decreased to 13, 18, and 20% for the 516 GG, 516 GT, and 516 TT genotypes, respectively. These findings indicate how dose reductions might be applied in patients with favorable genetic characteristics.

Improvement of the quality factor of RF integrated inductors by layout optimization

A systematic method to improve the quality (Q) factor of RF integrated inductors is presented in this paper. The proposed method is based on the layout optimization to minimize the series resistance of the inductor coil, taking into account both ohmic losses, due to conduction currents, and magnetically induced losses, due to eddy currents. The technique is particularly useful when applied to inductors in which the fabrication process includes integration substrate removal. However, it is also applicable to inductors on low-loss substrates. The method optimizes the width of the metal strip for each turn of the inductor coil, leading to a variable strip-width layout. The optimization procedure has been successfully applied to the design of square spiral inductors in a silicon-based multichip-module technology, complemented with silicon micromachining postprocessing. The obtained experimental results corroborate the validity of the proposed method. A Q factor of about 17 have been obtained for a 35-nH inductor at 1.5 GHz, with Q values higher than 40 predicted for a 20-nH inductor working at 3.5 GHz. The latter is up to a 60% better than the best results for a single strip-width inductor working at the same frequency.